Go To Global Site
Welcome to UCB in the United States

Oct

30

UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook

UCB tracking well towards full year financial outlook

Oct

29

UCB PharmD Fellowship Program Accepting Applications

Fellowship Preceptors (L to R): Oana Pop, Iram Hasan, Alexis Harper, Wanja Muthoga, Kate Kocik, Jennifer King, and Tanyja Porcha

Applications for our 2019-2021 Global Regulatory Affairs PharmD Fellowship Program are now closed. 

Mitch_H_1280x960

Oct

26

A Different Perspective on Clinical Studies

In this excerpt, Mitch Herndon, Patient Engagement Lead for UCB’s Global Clinical Sciences & Operations, talks about the importance of incorporating the patient perspective into clinical research studies. Read the full article on LinkedIn

Oct

23

Press Release: Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients

Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients

UCB_and_Biogen_logos_side_by_side_1280x960

Oct

23

Press Release: UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

Vivienne_1280x960_Blog

Oct

20

Breaking the Silence on Osteoporosis

It is estimated that a fragility fracture occurs every 3 seconds— totaling nearly 9 million fractures annually, worldwide. Oftentimes people think fragile bones are an inevitable part of getting older. But a broken hip or bone may more commonly be the result of an underlying condition: osteoporosis. So common that by the time you finish reading the title of this post, a fragility fracture due to osteoporosis has occurred.

Cimzia_1280x960_Logo

Oct

19

Press Release: UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthritis

• Oral presentation of results from C-AXSPAND, the first Phase 3 study to follow non-radiographic axial spondyloarthritis (nr-axSpA) patients for 52 weeks, demonstrated positive results for CIMZIA®(certolizumab pegol) in this patient population when added to common background medications

2---Man-falling2

Oct

18

Press Release: On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored

On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored

Oct

18

Press Release: UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase

Deonna_for_blog_1280x960

Oct

12

Disease Spotlight: Rheumatoid Arthritis

As part of World Arthritis Day, we’re shining a spotlight on rheumatoid arthritis (RA). Learn more about RA, which is just one of the many different types of arthritis that affect the people we’re honoring today.